[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Siena\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":229},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,69,97,130,157,180,207],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100587892","full-mouth-ultrasonic-debridement-carried-out-with-either-piezoelectric-or-magnetostrictive-device-100587892",false,"NCT06934291","Full Mouth Ultrasonic Debridement Carried Out With Either Piezoelectric or Magnetostrictive Device","Clinical and Patient-Centered Outcomes of Full-Mouth Ultrasonic Debridement for Periodontitis: A Randomized Controlled Trial Comparing Piezoelectric and Magnetostrictive Devices","Inclusion Criteria:\n\n* \\>18 years\n* periodontitis of stage 1 and 2\n* absence of systemic chronic disease\n\nExclusion Criteria:\n\n* anticoagulants treatment\n* antibiotic treatment 3 months before the screening visit","ALL","18 Years","80 Years",{"count":20,"type":21},52,"ESTIMATED","INTERVENTIONAL",[24],"NA","The treatment of periodontitis requires the removal of dental biofilm through both professional mechanical plaque removal and at-home oral hygiene practices. This study aims to compare clinical and psychological outcomes following professional treatment using either piezoelectric or magnetostrictive ultrasonic devices.",[27],"Periodontitis, Adult",[29,30,31],"periodontitis","patient centred outcomes","magnetostrictive","RECRUITING","2025-09-03",{"date":35,"type":36},"2025-09-10","ACTUAL",{"date":38,"type":36},"2025-03-31",{"date":40,"type":21},"2025-10",{"name":42,"class":43},"University of Siena","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100496171","gene-editing-as-a-therapeutic-approach-for-rett-syndrome-100496171","NCT05740761","Gene Editing as a Therapeutic Approach for Rett Syndrome","Personalized MECP2 Gene Therapy Using CRISPR\u002FCas9 Technology Coupled to AAV-mediated Delivery in 3D Cell Culture and KI Mice","MECPer-3D","Inclusion Criteria:\n\n* Patients -exclusively female- since the pathology is linked to the X chromosome, with a clinical diagnosis of Rett syndrome confirmed at the genetic level by the identification, through NGS analysis, for one of the recurrent mutations (mutational hotspots) in the MECP2 gene object of the study:\n\n  c. 473C\\>T - (p.(T158M)), c.502C\\>T (p(R168X)), c.763C\\>T (p.(R255X)), c.916C\\>T (p.(R306C));\n* Age above 6 months;\n* Availability of parents or legal guardians to provide free and informed consent to participate in the study\n\nExclusion Criteria:\n\n* NGS diagnosis with the normal outcome;\n* Positive NGS diagnosis for mutation in MECP2 but with the presence of a mutation different from those under study.\n* Unwillingness of parents or legal guardians to provide free and informed consent to participate in the study;","FEMALE","6 Months",{"count":56,"type":21},40,"OBSERVATIONAL","We designed the project to validate CRISPR\u002FCas9-based gene editing combined with AAV-based delivery for correction of the most common MECP2 mutations both in vitro and in vivo.",[60],"Rett Syndrome","2025-08-14",{"date":63,"type":36},"2025-08-20",{"date":65,"type":36},"2021-03-01",{"date":67,"type":21},"2026-03-01",{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100258043","loop-diuretic-therapy-in-acutely-decompensated-heart-failure-100258043","NCT02638142","Loop Diuretic Therapy in Acutely Decompensated Heart Failure","Continuous Versus Bolus Intermittent Loop Diuretic Infusion in Acutely Decompensated Heart Failure: Evaluation of Renal Function, Congestion Signs, BNP and Outcome","DIUR-AHF","Inclusion Criteria:\n\n* Patients over 18 years;\n* Patients with diagnosis of ADHF(dyspnea, orthopnea, peripheral edema or major fatigue and at least two clinical signs including rales, hepatomegaly, pulmonary congestion on chest radiography, jugular vein dilatation, or a third heart sound);\n* Blood BNP \\> 100 pg\u002FmL;\n\nADHF: Acute Decompensated Heart Failure; BNP: B-type Natriuretic Peptide; IV: IntraVenous; LVEF: Left Ventricular Ejection Fraction.\n\nExclusion Criteria:\n\n* Patients who receive more than 40 mg of IV furosemide;\n* End-Stage renal disease or renal replacement therapy;\n* Recent myocardial infarction (within thirty days of screening);\n* Systolic blood pressure \\\u003C 80 mmHg;\n* Creatinine levels \\> 4 mg\u002FdL;\n* Patients affected by sepsis, liver diseases, inflammatory diseases or neoplastic diseases.",{"count":78,"type":21},370,"DiurHF is a prospective, multicenter, observational, study that compares continuous with intermittent infusion of furosemide in patients admitted with a diagnosis of ADHF. Previous pilot study design was planned to anticipate a larger multicenter trial able to definitively evaluate the optimal loop diuretic use strategy in patients with ADHF.",[81],"Acute Heart Failure",[83,84,85,86,87],"loop diuretic","heart failure","renal dysfunction","congestion signs","BNP","2025-08-04",{"date":90,"type":36},"2025-08-08",{"date":92,"type":36},"2015-12",{"date":94,"type":21},"2028-01",{"name":42,"class":43},4,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":107,"studyType":57,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100454682","autoinflammatory-disease-alliance-registry-aida-100454682","NCT05200715","AutoInflammatory Disease Alliance Registry (AIDA)","Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis","AIDA","Inclusion Criteria:\n\n* to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype;\n* to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and\u002For classification criteria;\n* to be diagnosed with undifferentiated systemic AID;\n* to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria;\n* to be diagnosed with anterior or posterior non-infectious scleritis;\n* to be diagnosed with spondyloarthritis according to ASAS and\u002For New York criteria;\n* to be diagnosed with Castleman disease;\n\nExclusion Criteria:\n\n\\- informed consent\u002Fassent not provided by the patient and\u002For his\u002Fher legal representative.",{"count":106,"type":21},3500,"10 Years","Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic\u002Fmultifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings.\n\nIn this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.",[110,111,112,113,114,115,116,117,118,119,120],"Hereditary Autoinflammatory Diseases","Schnitzler Syndrome","Behcet Syndrome","PFAPA Syndrome","Still Disease","Autoinflammatory Syndrome, Unspecified","Uveitis","Scleritis","Vexas Syndrome","Spondyloarthritis (SpA)","Castleman Disease","2025-07-07",{"date":123,"type":36},"2025-07-10",{"date":125,"type":36},"2020-08-06",{"date":127,"type":21},"2030-08-06",{"name":42,"class":43},112,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":44},"100594349","postoperative-pain-evaluation-after-obturation-with-different-sealers-100594349","NCT07018284","Postoperative Pain Evaluation After Obturation With Different Sealers","Assessment of Postoperative Pain Incidence in Teeth Affected by Pulpitis, Necrosis, or Previously Treated, Following Obturation With Bioceramic or Resin-based Sealers","Inclusion Criteria:\n\nPatients aged 18 years and older. Teeth with a diagnosis of pulpal necrosis or irreversible pulpitis. Informed consent provided for data usage.\n\nExclusion Criteria:\n\n* Patients with systemic conditions that may impair healing (e.g., uncontrolled diabetes, immunosuppression).\n* Asymptomatic presentation\n* Teeth with root fractures, resorption, or open apices.\n* Incomplete clinical or radiographic records.\n* Cases with poor-quality radiographs or lack of standardization for evaluation",{"count":138,"type":21},270,[24],"This study aims to evaluate the incidence and intensity of postoperative pain in patients undergoing root canal treatment on teeth diagnosed with pulpitis, pulp necrosis, or with previous endodontic treatment. Teeth will be obturated using either bioceramic or resin-based sealers. The primary objective is to determine whether the type of sealer significantly influences the level of postoperative pain as reported by patients. Pain intensity will be assessed using the Visual Analogue Scale (VAS) at three time points: immediately after treatment, 24 hours, and 72 hours postoperatively. The findings are expected to provide clinical insight into which obturation material may be more effective in minimizing postoperative discomfort.",[142,143,144],"Periapical Periodontitis","Pulpitis","Necorsis",[146,147,148],"Bioceramic sealers","Resin-based sealers","Endodontics","2025-06-04",{"date":151,"type":36},"2025-06-12",{"date":153,"type":36},"2025-06-01",{"date":155,"type":21},"2026-01-30",{"name":42,"class":43},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":177,"leadSponsor":179,"locationsCount":44},"100594427","success-of-endodontic-treatment-with-different-obturation-techniques-and-sealer-cements-100594427","NCT07019298","Success of Endodontic Treatment With Different Obturation Techniques and Sealer Cements","Evaluation of the Success Rate of Endodontic Treatment Using Different Obturation Techniques and Root Canal Sealer Cements: A Randomized Controlled Trial","Inclusion Criteria:\n\nPatients aged 18 years and older. Teeth with a diagnosis of pulpal necrosis or irreversible pulpitis. Informed consent provided for data usage.\n\nExclusion Criteria:\n\n* Patients with systemic conditions that may impair healing (e.g., uncontrolled diabetes, immunosuppression).\n* Teeth with root fractures, resorption, or open apices.\n* Incomplete clinical or radiographic records.\n* Cases with poor-quality radiographs or lack of standardization for evaluation",{"count":138,"type":21},[24],"The present study aims to compare the radiographic success of endodontic treatment using Orstavik's criteria between two sealers: AH Plus (Dentsply DeTrey, Konstanz, Germany) and Neosealer Flo (Avalon Biomed, Bradenton, Florida, USA), as well as between two obturation techniques: continuous wave and single cone. The study includes 270 patients, with a minimum follow-up period of 6 months. Clinical and radiographic variables will be assessed, including quality of obturation, lesion healing, and restoration. The study seeks to determine if the use of bioceramic sealer is effective regardless of the obturation technique used, highlighting the importance of clinical follow-up to evaluate endodontic treatment success.",[143,168,142,169],"Periapical Lesions","Periapical Pathology",[148,171,172,173],"Endodontic Sealer","Calcium Silicate-Based Sealer","Ah Plus",{"date":175,"type":36},"2025-06-13",{"date":153,"type":36},{"date":178,"type":21},"2029-06-01",{"name":42,"class":43},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":188,"enrollmentInfo":189,"targetDuration":191,"studyType":57,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":197,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":206},"100516269","right-ventricular-dysfunction-in-chronic-heart-failure-100516269","NCT06002321","Right Ventricular Dysfunction in Chronic Heart Failure","Right Ventricular Dysfunction in Chronic Heart Failure: Clinical Laboratory and Echocardiographic Characteristics","RIVED-CHF","Inclusion Criteria:\n\n* All patients with a diagnosis of chronic heart failure made according to the recommendations of the ESC guidelines through the simultaneous presence of signs and symptoms of disease associated with BNP and NT proBNP levels \\> 100 and 300 pg\u002Fml respectively which are associated with a modest increase PAPS \\> 30 mmHg with or without right ventricular dilatation.\n\nExclusion Criteria:\n\n* Patients with dyspnea of non-cardiogenic origin, related to systemic respiratory diseases, pulmonary embolism, patients with primary pulmonary hypertension will be excluded.\n* Patients with heart failure linked to primary valvular pathologies or infiltrative pathologies, secondary and on a genetic basis, patients diagnosed with acute heart failure in non-optimized therapy for at least 3 months will also be excluded. - Patients with systemic inflammatory neoplastic diseases, advanced liver and kidney diseases awaiting transplantation will be excluded.","90 Years",{"count":190,"type":21},1000,"36 Months","The goal of this multi center observational prospective study is to analyze the concordance between the signs and symptoms of RHF and echocardiographic features of RVD in patient with heart failure. The main questions it aims to answer are:\n\n1. to assess the incidence of RVH and RVD in each HF subtypes.\n2. to evaluate prognostic impact ( in terms of cardiovascular mortality and HF hospitalization) of different RVD patterns during a mean followup period of 3 years\n3. To investigate the incidence of different RV maladaptation ( isolated RV dilatation, isolated Pulmonary hypertension, combined pattern) in each HF groups and the related outcome.\n\nParticipants will follow by direct check up visit and\u002For virtual visits every 6 months for a mean follow-up period of 3 years.",[194,195,196],"Chronic Heart Failure","Right Ventricular Dysfunction","Right Heart Failure","NOT_YET_RECRUITING","2023-08-18",{"date":200,"type":36},"2023-08-21",{"date":202,"type":21},"2023-09-01",{"date":204,"type":21},"2026-09-01",{"name":42,"class":43},14,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":44},"100359538","phase-3-standard-versus-super-extended-lymphadenectomy-after-neo-adjuvant-chemotherapy-for-gastric-cancer-100359538","NCT03961373","Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer","Neo-D2plus","Inclusion Criteria:\n\n* Age equal or greater than 18 years\n* IIA-IIIC histologically proven primary gastric adenocarcinoma, before the treatment with NAC. Not including gastro-oesophageal junction\u002Fcardia carcinoma but only Siewert 3, without any previous treatment (surgery and \u002F or chemotherapy) for this diagnosis\n* Lack in CT scan of following:\n\n  1. Mediastinal lymph nodes\n  2. Lung metastases\n  3. Peritoneal metastases\n  4. Liver metastases\n  5. Pleural effusion, ascites\n  6. Metastases to para-aortic lymph nodes No 16a2\u002Fb1\n  7. Metastases to lymph nodes located in the \"posterior\" area (8p, 12 b\u002Fp, 13)\n  8. Extra-regional lymph node metastases\n* ECOG performance status ≤ 2\n* No prior radio- or chemotherapy conflicting with the treatment of gastric cancer\n* No oesophageal invasion, or invasion \\\u003C=3cm\n* Negative peritoneal washing cytology findings and no peritoneal metastases in staging laparoscopy\n* No gastric stump cancer\n* No signs of cervical and subclavear lymph nodes or distal metastases\n* Patient's consent form obtained, signed and dated before beginning specific protocol procedures\n* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial\n\nExclusion Criteria:\n\n* Contraindications for any sort of appropriate chemotherapy according to local standards\n* Linitis plastica\n* Second uncontrolled malignant tumour (synchronous or metachronous (last 5 years) other than Cis or mucosal cancer\n* Neoplasms involving the esophago-gastric junction (Siewert types I and II)\n* Expected unresectability after neo-adjuvant treatment or progression in metastases\n* Emergency surgery due to bleeding or perforation\n* Uncontrolled infections\n* Other serious underlying medical conditions that could impair the ability of the patient to participate in the study\n* Pregnant or lactating women\n* Significant neurologic or psychiatric disorders\n* Severe cardiac illness (NYHA class IV)\n* Under treatment of systemic steroids\n* Participation in any other clinical trial that might interfere with the results of this trial\n* Lack of compliance\n* Inability to fill in questionnaires (insufficient command of language, dementia, lack of time)",{"count":215,"type":21},539,[217],"PHASE3","In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC). After conclusions of NAC and obtaining informed consent, they will be registered and randomized to receive surgical D2 vs. D2plus lymphadenectomy.",[220],"Locally Advanced Gastric Cancer","2019-05-21",{"date":223,"type":36},"2019-05-23",{"date":225,"type":36},"2018-11-05",{"date":227,"type":21},"2028-11-01",{"name":42,"class":43},""]